Keystone eSymposia Logo

Joint meeting with HIV Pathogenesis and Cure

HIV Vaccines

June 1-4, 2021 | 9:00AM EDT | 1:00PM UTC | 3:00PM CEST*
*Program is in development and subject to change



 Attention


The live portion of this conference has concluded and all presentations are now available for purchase on demand. Registrants to the live event may access this content anytime for up to 9 months following the event.


 Free Access to On Demand Content to Scientists from Low-and Middle-Income Countries


Keystone Symposia welcomes the global scientific community and aims to connect researchers within and across disciplines to accelerate the advancement of biomedical and life sciences. This form may be used for scientists from low- and middle-income countries of all career stages to determine eligibility and request free access to scientific content presented during recent eSymposia events. If eligible, you will be sent an access code for the On Demand content of the eSymposia event(s) of interest.


Apply Here


Development of effective prophylactic human immunodeficiency virus (HIV) vaccines are still urgently needed to halt the spread of the HIV/AIDS pandemic. However, development of these vaccines has proven to be a challenge that, despite intensive research efforts over the last 30 years, science has failed to surmount. Nevertheless, the prospects for an effective HIV vaccine have recently been transformed by a series of advances in science. These advances suggest that induction of broadly-reactive antibodies that confer protection via neutralization and/or neutralization-independent mechanisms and elicitation of cytotoxic (CD8) T cell responses can potentially eradicate the virus early after transmission and may ultimately prove to be achievable goals for drug development. 

This conference will bring together interdisciplinary investigators whose complementary expertise will synergize to inform HIV vaccine design and evaluation to discuss progress and outstanding challenges in areas such as: 1) The design of immunogens and strategies for optimization of germinal center responses to elicit HIV-1 broadly neutralizing antibodies; 2) Identifying prospects for harnessing other antibody effector functions to confer protection; 3) Developing approaches for eliciting rapidly-acting, efficacious HIV-specific CD8 T cell responses; and 4) How to use novel technologies, animal model systems and small-scale clinical trials to inform vaccine development efforts. This conference is being held jointly with HIV Pathogenesis and Cure. This pairing will provide an opportunity for interaction between investigators working in these related areas, and for joint discussion of therapeutic vaccination strategies.

Apply Here for Free On Demand Access

Pricing:

Regular Registration Rate: $275 USD
Student Registration Rate: $150 USD

Deadlines:

Abstract Submission
‣ For Short Talk Consideration: Passed
‣ For ePoster Presentation: Passed
Final ePoster / SciTalk Submission: Passed
Financial Aid Application: Passed

*Abstract submission is required in order to submit an ePoster and/or Scitalk

#VKSHIVVax21




Program Details



Keynote Speakers


d7b0a68aa1125b22898da9e5b2dc5199.png

M. Juliana McElrath
Fred Hutchinson Cancer Research Center


6cf9d8e752a964edc4ba4fdab198e309.png

Bruce D. Walker
Ragon Institute of MGH, MIT and Harvard



Speaking at this eSymposia


Priyamvada Acharya

Duke University, USA


Margaret E. Ackerman

Dartmouth College, USA


Julie Ake

Walter Reed Army Institute of Research, USA


Erica Andersen-Nissen

Cape Town HVTN Immunology Laboratory, South Africa


Dan H. Barouch

Beth Israel Deaconess Medical Center, USA


Facundo D. Batista

Massachusetts Institute of Technology and Harvard University, USA


Michael R. Betts

University of Pennsylvania, USA


Persephone Borrow

University of Oxford, UK


Lawrence Corey

Fred Hutchinson Cancer Research Center, USA


Mark M. Davis

Stanford University School of Medicine, USA


Barbara K. Felber

NCI, National Institutes of Health, USA


Guillaume J. Filion

University of Toronto Scarborough, Canada


Darrell J. Irvine

Massachusetts Institute of Technology, USA


Brad Jones

Weill Cornell Medicine, USA


Nichole R. Klatt

University of Minnesota, USA


Bette Korber

Los Alamos National Laboratory, USA


M. Juliana McElrath

Fred Hutchinson Cancer Research Center, USA


Andrew J. McMichael

Oxford University, UK


Beatriz Mothe

IrsiCaixa AIDS Research Institute-HIVACAT, Spain


Hugo Mouquet

Institut Pasteur, France


Michel C. Nussenzweig

HHMI/Rockefeller University, USA


Gabriel Ozorowski

The Scripps Research Institute, USA


Louis J. Picker

Oregon Health & Science University, USA


Keith Reeves

Duke University School of Medicine, USA


Rogier W. Sanders

University of Amsterdam and Weill Cornell Medical College, Netherlands


Kevin O. Saunders

Duke University, USA


William Schief

International AIDS Vaccine Initiative and The Scripps Research Institute, USA


Robin Shattock

Imperial College London, UK


Rasmi Thomas

U.S. Military HIV Research Program, USA


Sandhya Vasan

US Military HIV Research Program, USA


Bruce D. Walker

Ragon Institute of MGH, MIT and Harvard, USA






Sponsors


 

sponsor-carousel-merck.png

 




Additional Support



sponsor-carousel-bmgf.png

sponsor-carousel-nci.png

sponsor-carousel-novus.png

Funding for this conference was made possible (in part) by Grant No. [GRANT NUMBER - UPDATE] from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.




Media-in-Kind Support


sponsor-carousel-cellpress.png

sponsor-carousel-jcb-jem.png

sponsor-carousel-embo.png

sponsor-carousel-frontiers.png

Sponsor-Carousel-Leibert-Publishing.png

Sponsor-Carousel-nature-portfolio.png

Sponsor-Carousel-StemCell-Technologies.png

sponsor-carousel-scientist.png





The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.






#ScienceMustGoOn



This new virtual meeting format came out of difficult circumstances, but your commitment to scientific progress is what inspired us to launch Keystone eSymposia. In these virtual meetings, we are capturing the same innovative essence of our in-person meetings that you've all created as a scientific community.  Here, Debbie Johnson, our CEO, explains how we're going to do that.




Donate to Keystone Symposia


Donate to Keystone Symposia